740584
Last Update Posted: 2018-10-30
Recruiting has ended
Females accepted | 18 Years-45 Years |
12 Estimated Participants | No Expanded Access |
Interventional Study | Accepts healthy volunteers |
Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.
To assess the retention and anti-viral activity (human immunodeficiency virus (HIV) and herpes simplex virus 2 (genital herpes, HSV-2) of SPL7013 in cervicovaginal samples taken up to 24 hours after administration of 3% SPL7013 in the vagina. There is no hypothesis for this study.
Eligibility
Relevant conditions:
HIV Infections
HSV-2 Genital Herpes
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov